AXGN · 10-Q · 2026Q1 · Full report
Reimbursement and Payer Mix
Axogen, Inc. · 2026-04-28 · Importance 85 · Surprise 92
The company reported positive coverage decisions from two major U.S. commercial insurers, Cigna and Elevance Health, which can increase payer access and reduce reimbursement uncertainty in the U.S. market. Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code that increased Avance facility reimbursement by 40% year‑over‑year to $9 for hospital outpatient procedures and by 35% to $6 for ASC‑based procedures, directly affecting per‑procedure reimbursement rates. These payer and CMS actions are expected to support revenue growth and improved commercial economics in the U.S. going forward. The company states it derives substantially all revenues from U.S. customers, so these changes materially affect its principal market.
Key facts
- Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code that increased Avance facility reimbursement 40% year-over-year to $9 for hospital outpatient procedures
- Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code that increased Avance facility reimbursement 35% year-over-year to $6 for ASC-based procedures
- Received positive coverage decisions from Cigna and Elevance Health
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code that increased Avance facility reimbursement 40% year-over-year… |
| revenue | positive | realized | — | Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code that increased Avance facility reimbursement 35% year-over-year… |
| revenue | positive | probable | — | Received positive coverage decisions from Cigna and Elevance Health |